Preface
Preface
Translational Lung Cancer Research
2014;
3
(5)
:269
.
(21 October 2014)
Review Article
Lung cancer molecular epidemiology in China: recent trends
Translational Lung Cancer Research
2014;
3
(5)
:270-279
.
(21 October 2014)
Tobacco control in Poland—successes and challenges
Translational Lung Cancer Research
2014;
3
(5)
:280-285
.
(21 October 2014)
Implementation of lung cancer screening: promises and hurdles
Translational Lung Cancer Research
2014;
3
(5)
:286-290
.
(21 October 2014)
Molecular testing in lung cancer in the era of precision medicine
Translational Lung Cancer Research
2014;
3
(5)
:291-300
.
(21 October 2014)
Minimal requirements for the molecular testing of lung cancer
Translational Lung Cancer Research
2014;
3
(5)
:301-304
.
(21 October 2014)
Adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer
Translational Lung Cancer Research
2014;
3
(5)
:305-310
.
(21 October 2014)
Clinical trials for lung cancer in China
Translational Lung Cancer Research
2014;
3
(5)
:311-316
.
(21 October 2014)
CELCC 2014 Abstracts
O1. EGFR, EML4-ALK and ROS 1 testing in Austrian patients with NSCLC: a multicentre study
Translational Lung Cancer Research
2014;
3
(5)
:AB001
.
(21 October 2014)
O2. Frequency of EGFR gene mutations in patients with NSCLC in Czech Republic
Translational Lung Cancer Research
2014;
3
(5)
:AB002
.
(21 October 2014)
O3. Registry study in NSCLC patients with EGFR, ALK, or ROS1 mutations
Translational Lung Cancer Research
2014;
3
(5)
:AB003
.
(21 October 2014)
O4. Central data collection of management NSCLC stage III patients—study ongoing
Translational Lung Cancer Research
2014;
3
(5)
:AB004
.
(21 October 2014)
O5. Prognostic significance of clinical T2aN0M0 GGO—dominant lung adenocarcinoma
Translational Lung Cancer Research
2014;
3
(5)
:AB005
.
(21 October 2014)
O6. Circulating tumor cells in the peripheral blood predict poor prognosis in surgically treated non-small cell lung cancer patients
Translational Lung Cancer Research
2014;
3
(5)
:AB006
.
(21 October 2014)
O7. Advantages and disadvantages of Cisplatin or carboplatin in adjuvant chemotherapy of NSCLC
Translational Lung Cancer Research
2014;
3
(5)
:AB007
.
(21 October 2014)
O9. Results of multimodality therapy including radical resections for Pancoast tumors: a retrospective study in high-volume center
Translational Lung Cancer Research
2014;
3
(5)
:AB008
.
(21 October 2014)
O10. Allele-specific real-time PCR detection of EGFR exon 19 and 21 mutations in various clinical non-small cell lung cancer specimens
Translational Lung Cancer Research
2014;
3
(5)
:AB009
.
(21 October 2014)
O11. The results of gefitinib in front line treatment of Caucasian patients with NSCLC in the Czech Republic: analysis according to activated mutations location
Translational Lung Cancer Research
2014;
3
(5)
:AB010
.
(21 October 2014)
O12. Survival of patients with advanced EGFR-mutated NSCLC treated with EGFR TKIS in routine clinical practice
Translational Lung Cancer Research
2014;
3
(5)
:AB011
.
(21 October 2014)
O13. Subtype-specific KRAS mutations in advanced lung adenocarcinoma
Translational Lung Cancer Research
2014;
3
(5)
:AB012
.
(21 October 2014)
P1. Molecular subclassification of NSCLC based on hsa-mir-205 and hsa-mir-21 expression using real time PCR
Translational Lung Cancer Research
2014;
3
(5)
:AB013
.
(21 October 2014)
P2. VATS sentinel node biopsy reduces the need for systematic mediastinal lymphadenectomy in early stage NSCLC
Translational Lung Cancer Research
2014;
3
(5)
:AB014
.
(21 October 2014)
P3. Therapeutic efficacy of single incision thoracoscopic surgery (SITS) for stage I lung cancer
Translational Lung Cancer Research
2014;
3
(5)
:AB015
.
(21 October 2014)
P4. Aurora kinase MRNA level and gene copy number alterations in stage I-III. A non-small cell lung cancer
Translational Lung Cancer Research
2014;
3
(5)
:AB016
.
(21 October 2014)
P5. Multidisciplinary thoracic tumor board conferences—review of the literature and institutional experience
Translational Lung Cancer Research
2014;
3
(5)
:AB017
.
(21 October 2014)
P6. Induction chemo- or chemoradiotherapy followed by resection for N2 positive NSCLC—a retrospective study
Translational Lung Cancer Research
2014;
3
(5)
:AB018
.
(21 October 2014)
P7. Left carinal pneumonectomy with right bronchoplastic reconstruction via left thoracotomy
Translational Lung Cancer Research
2014;
3
(5)
:AB019
.
(21 October 2014)
P8. Efficacy of first-line pemetrexed/platinum chemotherapy in the treatment of advanced NSCLC in routine clinical practice
Translational Lung Cancer Research
2014;
3
(5)
:AB020
.
(21 October 2014)
P9. Response to gefitinib in advanced non-small cell lung cancer patients (NSCLC) with rare epidermal growth factor (EGFR) mutations—serbian experience 2011-2014
Translational Lung Cancer Research
2014;
3
(5)
:AB021
.
(21 October 2014)
P10. Influence of patient and tumor characteristics on the outcome of gefitinib therapy in advanced lung adenocarcinoma in two centers in Serbia
Translational Lung Cancer Research
2014;
3
(5)
:AB022
.
(21 October 2014)
P11. Efficacy and safety of erlotinib in advanced squamous cell lung cancer
Translational Lung Cancer Research
2014;
3
(5)
:AB023
.
(21 October 2014)
P12. Long term treatment with erlotinib in advanced non-small cell lung cancer patients
Translational Lung Cancer Research
2014;
3
(5)
:AB024
.
(21 October 2014)
P13. Epidemiologic, and therapeutic strategy of treated non-small cell lung cancer elderly patients in a single institution
Translational Lung Cancer Research
2014;
3
(5)
:AB025
.
(21 October 2014)
P14. Elderly patients with NSCLC with brain mets-need for combined targeted therapy
Translational Lung Cancer Research
2014;
3
(5)
:AB026
.
(21 October 2014)
P15. Crizotinib in metastatic ALK-positive lung cancer—results from clinical practice in Slovakia
Translational Lung Cancer Research
2014;
3
(5)
:AB027
.
(21 October 2014)
P16. Is type of EGFR mutation predictive for incidence and survival in lung adenocarcinoma patients with brain metastases?
Translational Lung Cancer Research
2014;
3
(5)
:AB028
.
(21 October 2014)
P17. Prognostic significance of serum tumor markers in patients with advanced-stage NSCLC treated with pemetrexed-based chemotherapy
Translational Lung Cancer Research
2014;
3
(5)
:AB029
.
(21 October 2014)
P18. Predictive role of serum tumor markers NSE and TK in patients with advanced-stage NSCLC treated with EGFR-TKIs
Translational Lung Cancer Research
2014;
3
(5)
:AB030
.
(21 October 2014)
P19. Overall survival in advanced lung cancer patients proposed to receive initial chemotherapy according to actual chemotherapy delivery
Translational Lung Cancer Research
2014;
3
(5)
:AB031
.
(21 October 2014)
P20. The role of statins in patients with advanced NSCLC harboring KRAS mutation treated with EGFR-TKIs
Translational Lung Cancer Research
2014;
3
(5)
:AB032
.
(21 October 2014)
P21. Immunohistochemistry versus DNA testing for detection of EGFR mutations and ALK rearrangements in lung adenocarcinoma patients
Translational Lung Cancer Research
2014;
3
(5)
:AB033
.
(21 October 2014)
P22. The serum levels, phenotypes and expression of alpha-1-antitrypsin in non-small cell lung cancer—pilot study
Translational Lung Cancer Research
2014;
3
(5)
:AB034
.
(21 October 2014)
P23. PET-CT confirms high rate of complete remissions among patients with advanced EGFR positive NSCLC treated with intercalated therapy
Translational Lung Cancer Research
2014;
3
(5)
:AB035
.
(21 October 2014)
P24. Epidemiologic, clinical characteristics of elderly non-small lung cancer patients treated in a single institution
Translational Lung Cancer Research
2014;
3
(5)
:AB036
.
(21 October 2014)
P25. In vitro evaluation of the anticancer activity of ganetespib in combination with standard chemotherapeutics in small cell lung cancer (SCLC) cell lines
Translational Lung Cancer Research
2014;
3
(5)
:AB037
.
(21 October 2014)
P26. Well differentiated neuroendocrine tumors of the lung—our experience
Translational Lung Cancer Research
2014;
3
(5)
:AB038
.
(21 October 2014)
P27. Small cell lung cancer and combined sparoganosis were suspected by multiple distant metastasis in PET-CT imaging of patient with colon cancer
Translational Lung Cancer Research
2014;
3
(5)
:AB039
.
(21 October 2014)
P28. Prediction of prognosis for small cell lung cancer based on genome-wide methylation analyses
Translational Lung Cancer Research
2014;
3
(5)
:AB040
.
(21 October 2014)
P29. Oral topotecan in small cell lung cancer: treatment related side effects
Translational Lung Cancer Research
2014;
3
(5)
:AB041
.
(21 October 2014)
P30. Ki-67 expression in lung carcinoid tumors
Translational Lung Cancer Research
2014;
3
(5)
:AB042
.
(21 October 2014)
P31. Outcome after trimodality therapy with intracavitary hydrogen peroxide therapy in malignant pleural mesothelioma
Translational Lung Cancer Research
2014;
3
(5)
:AB043
.
(21 October 2014)
P32. Histological evaluation of mesotheliomas
Translational Lung Cancer Research
2014;
3
(5)
:AB044
.
(21 October 2014)
P33. Potential clinical relevance of in vitro migratory activity in malignant pleural mesothelioma
Translational Lung Cancer Research
2014;
3
(5)
:AB045
.
(21 October 2014)
P34. Exploring cell plasticity in malignant pleural mesothelioma
Translational Lung Cancer Research
2014;
3
(5)
:AB046
.
(21 October 2014)
P35. Fibroblast growth factor signals and their connection to micrornas in malignant pleural mesothelioma
Translational Lung Cancer Research
2014;
3
(5)
:AB047
.
(21 October 2014)
P36. The prognostic potential of circulating and tissue activin A level in malignant pleural mesothelioma
Translational Lung Cancer Research
2014;
3
(5)
:AB048
.
(21 October 2014)
P37. Surgical strategy for stage III thymoma by video assisted thoracoscopic surgery (VAT-T) with lateral thoracotomy
Translational Lung Cancer Research
2014;
3
(5)
:AB049
.
(21 October 2014)
P38. Extraesophageal reflux disease and lung cancer
Translational Lung Cancer Research
2014;
3
(5)
:AB050
.
(21 October 2014)
P39. Management of respiratory symptoms in patients with advanced lung cancer
Translational Lung Cancer Research
2014;
3
(5)
:AB051
.
(21 October 2014)
P40. Applying digital tomosynthesis (DTS) to diagnose lung cancer and follow up patients
Translational Lung Cancer Research
2014;
3
(5)
:AB052
.
(21 October 2014)
P41. Scedosporium apiospermum mycetoma in a lung cancer patient—case report
Translational Lung Cancer Research
2014;
3
(5)
:AB053
.
(21 October 2014)
P42. Multiple neoplasms consist of lung cancer and hematological malignancies
Translational Lung Cancer Research
2014;
3
(5)
:AB054
.
(21 October 2014)
P43. Therapy-related leukemia after lung cancer therapy
Translational Lung Cancer Research
2014;
3
(5)
:AB055
.
(21 October 2014)
P44. Activin A is novel circulating biomarker in lung cancer
Translational Lung Cancer Research
2014;
3
(5)
:AB056
.
(21 October 2014)
P45. New method of brachytherapy catheter stabilization in proximal trachea
Translational Lung Cancer Research
2014;
3
(5)
:AB057
.
(21 October 2014)
P46. Use of 18-FDG PET/CT in the radiotherapy planning of lung cancer—our updated experiences
Translational Lung Cancer Research
2014;
3
(5)
:AB058
.
(21 October 2014)
Disclosure:
The focused issue “The 14th Central European Lung Cancer Congress (CELCC)” was commissioned by the editorial office, Translational Lung Cancer Research without any sponsorship or funding. Robert Pirker and Caicun Zhou served as the unpaid Guest Editors for the focused issue.
